Key Highlights

  • First patient dosed in the IDE849 Phase 1 trial announced March 30, 2026.
  • Phase 1 data covering solid tumors and small cell lung cancer due at ESMO.
  • Presentation window scheduled for October 23-27.
  • IDEAYA shares trade near $36.01, with a market value of about $3.16 billion.

IDEAYA Biosciences (NASDAQ: IDYA) is scheduled to present first Phase 1 data for IDE849, also known as SHR-4849, in solid tumors and small cell lung cancer at the ESMO 2026 congress, running October 23-27.

What Happened

The company announced the first patient had been dosed in the IDE849 Phase 1 trial on March 30, 2026.

The upcoming ESMO presentation will mark the first disclosure of clinical data from that trial, covering solid tumors broadly as well as small cell lung cancer specifically.

Market Reaction

IDEAYA Biosciences, valued at approximately $3.16 billion, traded near $36.01 per share, up $0.08, or 0.22%, according to the disclosed pipeline database.

Outlook

First Phase 1 data on IDE849 is scheduled to be presented at ESMO between October 23 and 27, 2026.

What is IDE849?

IDE849, also known as SHR-4849, is a Phase 1 clinical-stage candidate from IDEAYA Biosciences being studied in solid tumors and small cell lung cancer.

When did IDEAYA dose its first patient in the IDE849 trial?

The company announced the first patient was dosed on March 30, 2026.

When will IDEAYA present initial IDE849 data?

First Phase 1 data is scheduled for presentation at the ESMO 2026 congress, held October 23-27.